A new genome sequence study suggests sequence conservation is more common in HPV16 isolates from individuals with cancer or pre-cancerous conditions.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
The trial will evaluate a single CTC analysis pipeline that incorporates cell enumeration and isolation systems from Menarini-Silicon Biosystems.
In Nature this week: genes needed for effective cancer immunotherapy, and more.
The consortium aims to advance the use of genomics in the clinic, with a particular focus on diverse and underserved patient populations.
The National Cancer Institute-led team used a CRISPR-based approach to identify genes like APLNR that, when mutated, make cancers resistant to immunotherapy.
Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
The study is the pediatric counterpart to an ongoing precision medicine study in cancer patients 18 years and older.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The agencies said they're aiming to "accelerate the development of proteogenomic technologies and biomarkers, as it relates to precision medicine in cancer."
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.